Showing 4291-4300 of 8129 results for "".
- Angina Drug Ranolazine Improves the Efficacy of Current Treatments for Melanoma in Mouse Modelshttps://practicaldermatology.com/news/angina-drug-ranolazine-improves-the-efficacy-of-current-treatments-for-melanoma-in-mouse-models/2461926/The heart drug ranolazine may improve the efficacy of current therapies for melanoma in mouse models of this disease, according to research out of Navarrabiomed Biomedical Research Center, the Institute of Neurosciences CSIC-UMH, and IRB Barcelona. The development of future clinical tri
- DermaSensor Device Can Help Detect Skin Cancer Across Skin Toneshttps://practicaldermatology.com/news/dermasensor-device-can-help-detect-skin-cancer-across-skin-tones/2461924/DermaSensor's handheld Elastic Scattering Spectroscopy (ESS) device can help detect skin cancer in patients across different Fitzpatrick skin types, according to new research presented at the 2023 American Academy of Dermatology (AAD) Innovation Academy meeting. DermaSensor is desig
- Acclaro Medical Rolls Out UltraClear Laser-Coring Technologyhttps://practicaldermatology.com/news/acclaro-medical-rolls-out-ultraclear-laser-coring-technology/2461920/Acclaro Medical is rolling out UltraClear Laser-Coring at the 2023 AAD Innovation Academy in Tampa, Fla. UltraClear, a cold, ablative fiber laser, enables tissue coring to improve deep wrinkles, deep scars, and other age-related issues on all skin types with minimal disco
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Skin Cancer-related Mutations Higher in the UK Than Singaporehttps://practicaldermatology.com/news/skin-cancer-related-mutations-higher-in-the-uk-than-singapore/2461909/People in the UK have facial skin that is far more DNA damaged from the sun than people in Singapore, explaining the far higher risk of developing basal and squamous cell carcinomas in the UK, new research suggests. When researchers from the Wellcome Sanger Institute and their collabora
- Replimune, Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 and INCB99280 in CSCChttps://practicaldermatology.com/news/replimune-incyte-enter-into-clinical-trial-collaboration-and-supply-agreement-to-evaluate-rp1-and-incb99280-in-cscc/2461908/Replimune Group, Inc. and Incyte are collaborating to a study RP1 in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor, in cutaneous squamous cell carcinoma (CSCC) and in other cancer types,
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and accept